LRRC6P1

Across TCGA pan-cancer cohorts, LRRC6P1 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated LRRC6P1 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LRRC6P1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LRRC6P1 expression acts as an unfavorable survival marker.

LIHC, OV, and LUSC are the cancer types where LRRC6P1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.051	0.772	<.001	63	view →
OV	OS	Tertile	IV	0.007	0.760	<.001	36	view →
LUSC	OS	Tertile	All	0.205	0.660	.010	36	view →
SKCM	OS	Tertile	III,IV	0.288	0.707	.012	33	view →
UCEC	DFS	Tertile	IV	0.206	0.704	.033	30	view →
BLCA	OS	Tertile	III,IV	0.141	0.581	.011	18	view →
BRCA	DFS	Tertile	II,III,IV	0.358	0.889	<.001	18	view →
LGG	DFS	Tertile	All	0.089	0.845	<.001	12	view →
STAD	DFS	Tertile	All	0.538	0.733	.041	9	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

LRRC6P1–LIHC (OS)

Open the LIHC breakdown →